Avanos Medical
AVNS
AVNS was delisted on the 24th of July, 2026.
468 hedge funds and large institutions have $1.59B invested in Avanos Medical in 2014 Q4 according to their latest regulatory filings, with 468 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.96% more ownership
Funds ownership: 0% → 74.96% (+75%)
18% less call options, than puts
Call options by funds: $7.47M | Put options by funds: $9.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$125M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$112M |
| 3 |
GC
Greenlight Capital
New York
|
+$92.5M |
| 4 |
RP
RR Partners
New York
|
+$74.7M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$74.3M |
Top Sellers
AVNS Hedge Fund Activity: Q4 2014 in Review
468 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Avanos Medical (AVNS) for Q4 2014, worth a combined $1.59B.
Buyers outnumbered sellers: 468 funds opened new AVNS positions and 0 closed out — a net gain of 468 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $125M.
- 468 institutional investors held Avanos Medical (AVNS) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $1.59B of Avanos Medical stock for Q4 2014.
- 468 funds opened new Avanos Medical positions in Q4 2014 and 0 closed out, a net change of +468 holders.
- The largest Avanos Medical buyer in Q4 2014 was T. Rowe Price Associates, an estimated $125M added.
Based on aggregated 13F filings for Q4 2014.